Abstract
The ALLHAT trial (Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial) is the largest study ever to focus on the treatment of patients with hypertension and the authors’ conclusions have been widely published in the press. However, only a small part of the information published in the newspapers and magazines has focused on the results obtained by the study and great emphasis has instead been given to interpretations based on secondary endpoints. A similar effect on the primary endpoint (fatal and nonfatal coronary artery disease) was observed with all three of the studied drugs in spite of significantly lower systolic blood pressure in the chlorthalidone group.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: High Blood Pressure & Cardiovascular Prevention
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
